#USA #Seattle #CVR #Atossa Therapeutics #股票

Atossa Therapeutics Announces Stapled Contingent Value Rights for Investors

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a biopharmaceutical company at the clinical stage, has confirmed a significant development for its shareholders. As of the close of business on October 19, 2026, each share of Atossa common stock will commence trading with an accompanying stapled Contingent Value Right (CVR). This announcement aims to offer investors an opportunity to engage in the potential future value of Atossa's burgeoning projects in oncology and other areas with pressing medical needs.

Understanding Stapled Contingent Value Rights (CVR)

The CVR structure introduces a new dimension to Atossa's stock. Each share outstanding on the record date will be paired with a CVR, enabling shareholders to participate in the company’s endeavors linked to a qualifying priority review voucher (PRV) from the FDA. The idea is to ensure that any increase in value aligns directly with ownership of Atossa’s stocks, thereby presenting a potentially lucrative opportunity for investors.

The CVRs will remain attached or "stapled" to the Atossa common stock, which means they can only be sold in conjunction with the shares they are tied to. This restriction fosters a tight correlation between the stock and the value of the CVRs, creating a cohesive investment framework. Only shares issued post-record date will also have a CVR attached, solidifying the deadline's significance.

Potential Value and Company Statements

The move was articulated by Steven C. Quay, M.D., Ph.D., Chairman, President, and CEO of Atossa. He highlighted that the record date serves as a pivotal juncture that allows shareholders to benefit from the contractual opportunity afforded by the CVRs linked to the first qualifying PRV. By linking these rights to the stock, Atossa aims to ensure that every shareholder can effectively engage in the anticipated value generated through its future success.

Atossa's main product candidate, (Z)-endoxifen, is currently under development for various potential applications, including oncology treatment and rare diseases. The company has received FDA's Rare Pediatric Disease Designation, indicating a pathway to earn a PRV if their developmental projects achieve FDA approval. However, it is crucial to note that no product candidate from Atossa has yet received FDA approval, and potential market benefits from the CVR structure hinge upon successful application submissions and regulations.

Key Features of the CVR Agreement

• - Stapled Rights: One CVR is assigned to each share of common stock, ensuring they transfer together.
• - Ongoing Participation: Shares issued after the record date will also have the CVR attached, preserving the opportunity for new investors.
• - Financial Framework: CVR holders will receive up to 25% of net proceeds from the sale of the first qualifying PRV, with an aggregate cap of $50 million, fostering investor engagement.

The company retains discretion over its development and commercialization strategies, including when and if to monetize any potential PRVs awarded. Shareholder payments from the CVRs will depend on several factors that include market conditions and Atossa’s strategies moving forward.

Conclusion

Atossa Therapeutics' announcement marks a strategic progression aimed at enhancing shareholder value while navigating the intricate field of drug development. By innovating with financial instruments like CVRs, the company intends to align its growth potential with its investors' interests, thereby encouraging sustained investment in a promising corporate landscape. As Atossa continues to develop its products and pursue FDA approvals, stakeholder engagement will play a vital role in realizing the potential of these contingent value rights.